Member Info for SocialistB

@PeterBuc

So true, so true.

Today did feel like a kick in the teeth.

But, I blame no other then the market and how the market works and can be misused.

We are now funded.

We can now move into clinical trials.

And if I remember correctly then Prevail Partners would first stump up some cash when we did likewise.

But I could remember wrong.

However, if I don't, then further funding might soon be announced in regard to CAR-T.

It is noteworthy that CBR was not mentioned in today's RNS.

In the future, I expect more more funding news to come in regard to this hopefully fantastic invention, which is 100% owned by Hemogenyx.

@Bline59

I think you are wrong.

We have not gone 3 years back.

Share price wise you might be correct, I haven't checked what it was 3 years ago, but it is definitely not where we ought to be.

So from that point of view, I agree with you.

However, Hemogenyx has improved so much over the past 3 years, we are much more advanced and in s totally envious position with regard to the science and how it has proven to be effective with the trials undertaken by today's date.

Today it has even been announced that we now have the funding needed to progress our HEMO CAR+T candidate.

But I agree the funding has not been obtained in the way or on terms most of us had hoped .

But that just shows how difficult the market is.

I fully believe that had a better offer (IE less dilution and no restrictive covenants) been on the table from a major pharma, the BOD would have accepted it.

But I have to assume that going to the market, even though it was manipulated, as stated in the RNS was the best option for Hemogenyx and thereby us shareholders.

That just goes to show how detrimental any potential offer from s major must have been at this stage, if there was one in the first place.

That is all assumption on our part.

Not exactly a once in a lifetime opportunity, but how often does an opportunity like what HEMOGENYX has to offer present itself to us private investors or big pharma for that matter.

I'd argue not very often.

I therefore see poetic beauty in a RNSs tomorrow on the 29th of February.

Also, something that does not happen that often.

Ideally an RNS tomorrow would deliver manna from heaven (or a big pharmaceutical company)

But I'd happily settle for anything that provide certainty about the way forward.

Even a discounted placing, if there was nothing of interest on the table, due to terms and conditions.

Either way if something special is delivered on tomorrow's special day, then that has been achieved in the same calendar month as Hemogenyx became clinical, or at least the hold was lifted.

I hope for something special on a very special day.

All LTHs

We have had fantastic communication from Hemogenyx.

Look at the recent RNS's.

To me it looks like you want information that is probably prohibited to give.

I assume telling the market they are in negotiationsis a no go area at this very point in time

Even if it isn't, then if negotiations does not materialize it leaves a bad taste in the mouth and the company looking bad.

I say, enjoy the silence.

All Laths should have an idea about what is happening, we all know we need funds to take our candidates further.

@mjng

Just to play the devil's advocate for a moment.

Although I agree that if we get a good funding on good terms then the share price should rise, as it simply ought to behave that way.

But, then I have thought and stated the same in regard to the following issues.

- becoming clinical

- positive CBR news

And both has happened.

But there has not been the desired permanent price rise that I had hoped for.

The truth is that there won't be s sustained price rise until there is substantial more buys at ever higher prices then what is being sold.

Or maybe even worse, maybe in the worst of worst case scenarios there would not be any share price rise at all, and the only possible way to get paid more for our shares would be to accept a buy out offer at a higher price.

Theoretically, it might be possible.

Realistically, I doubt it very much though.

It's just that the market has not yet discovered Hemogenyx's potential and/or are not willing to take their chances currently.

I am sure that will change.

I HOPE it will change.

As I said in the beginning, just playing devil's advocate.

Full disclosure, I had expected an RNS spelling out how we were going to be funded in regard to HEMO CAR-T a long time ago.

In fact, I thought it highly likely that it would be announced later on that very same day it was announced the clinical hold was lifted, 2 weeks ago.

That did not happen, but I am not worried in the slightest bit that no funding won't be forthcoming.

I assume that it is taking time, because one or more decent offers of funding has been presented to HEMOGENYX recently.

It would be in any majors interest to get on Hemogenyx's good side and get a foot through the door.

It would be a smart move to be generous with support in regard to HEMO CAR-T and CDX in the hope to get a slice of the CBR pie later on.

Exactly Ntl101.

Being multi mineral focused could potentially have some serious benefits.

If gold is down, not favoured by the market, then hopefully one of the other minerals are more in focus.

If all your various mineral deposits and mines are located in the Patterson region it might be easy to move people around to where it is more profitable to mine at any given time.

And there are a couple of interessant undervalued opportunities in the Patterson region, if you ask me.

With the BOD that we have in place, I would like to see a buying or merger spree.

As long as it is done with a measured risk ratio.

Not doing so, would in my view constitute a waste of a fantastic BOD.

Allow I like a lot of what is said in the 2 first posts, I would like to offer a counter argument.

If there is a chance to buy another company, who has found a great deposit of something interesting, and it is hugely undervalued, then it makes sense to buy it.

Especially if it is not gold, as Greatland is starting to embrace other minerals as well.

As Havieron us being managed by Newmont, there is not much Greatland and the BOD can do.

So, it makes perfect sense to me that there is a focus on drilling elsewhere and hopefully find something, especially because it does take a long time to establish a working mine.

Personally, I would hate to see Hemogenyx be taken over by a major.

I want to see the company grow from strength to strength, year by year.

And eventually become a major ourselves.

I want to be part of that journey.

I would much prefer that we partner up with various majors and have collaborations with them on some CBR products and regions.

Like one major has the market for Covid-19 in Asia, another has it Europe, then America etc

Then the same goes for Ebola, Zika, Marburg etc

An advantage to this model, if Hemogenyx gets to keep the intellectual rights to what is discovered and changed in a JV with one company is that there can be different solutions tried with the various partners.

Hemogenyx has shown with the CDX collaboration with Eli Lilly that it is possible to acquire and/or maintain the intellectual property when collaborating on a project.

If CBR works on human beings, becoming a major ourselves is where the true value lies.

And selling to a major at this stage would be like selling for peanuts.

Look at the trajectory of Microsoft, look where they are today.

Had it been sold to IBM in the early days, even with a good premium, well what a historic loss that would have been for their shareholders.

I admit it will take time for Hemogenyx to become a major and unfortunately not everyone has that amount of patience.

So, for those who lacks the patience, I beg of you:

If you're going to sell for peanuts, please ensure it is first class rated peanuts.

If CBR works, in my view we cannot even start considering peanuts to be in the first class category if we are offered less then 5 pounds a share.

Less then 6 Billion for Hemogenyx, if CBR works is a steal.

And it is us the shareholders that are being robbed.

(But at least it is self inflicted:-)

Hear hear, well spoken

I have to whole heatedly disagree.

If there was enough buyers, then the price should rise.

Simple question of supply and demand.

The demand is not there yet.

The market that are willing to invest long term has yet to discover what HEMO is offering.

@ BigBone

Is the share price due to manipulation?

I get the temptation to think so.

We have in less than 1 week had 2 fantastic RNS’s and the share price went up to over 7 pence based on the first and despite yesterday's fantastic news it has now been under 3 pence.

It is hard to fathom.

And I can see why people are tempted to think manipulation is happening.

But behind every manipulation, there must be a motive.

If the motive is to make a profit, then you do not achieve that by selling at these prices, unless of course there is a big SHORT out there.

If the motive is to increase one % of the company then it is risky to first sell out of your holding and hope that you can buy the same amount plus more later on.

I hope that there is someone out there who can enlighten me as to how anyone would otherwise benefit from selling out of their holding or lent shares.

Otherwise, I’ll take my tin hat off and simply conclude that we have not yet seen enough new investors take a holding in the company and that the recent fluctuations are simply down to traders earning and taking their profit.

Soon enough we will see the kind of long-term investors that we are hoping for, the news has been brilliant recently.

But I admit that in addition to new long-term investors, who need to do their due diligence before piling in big time, we also need clarification on funding.

I am also certain it has already been worked on for quite some time now.

All we need is a bit more patience.

What a fantastic RNS to wake up to.

No wonder it was not released yesterday on the 13th, why take the risk and alienate the superstitious among investors.

No, much better to bring out the good news on a lover’s day.

Because, what is not to love about today’s news.

CBR has moved out of the petri dish. And are no longer just showing a positive effect on cells.

It has now shown that it works in animals.

That is an important step before we can start testing it on humans.

Some highlights from today’s RNS

(but hey, you might as well read it all as this is about half of it anyway)

“Hemogenyx Pharmaceuticals plc (LSE: HEMO), the clinical stage biopharmaceutical group, announces that it has demonstrated in vivo that its proprietary Chimeric Bait Receptor ("CBR") can be delivered intranasally in the form of messenger RNA ("mRNA") for the potential treatment of airborne viral infections.”

“To satisfy real-world requirements for the deployment of such countermeasures, they must be both easy to administer and have a long shelf life at ambient temperatures. “

“Our team of scientists has demonstrated in vivo that mRNA encoding a CBR-based therapeutic can be mixed with a polymer and a solvent at room temperature”

“Once administered, nanoparticles were shown to successfully deliver mRNA into the immune cells of the URT and lungs. The immune cells in turn begin making CBR molecules within hours post-application, potentially becoming active "defenders" against airborne infections.”

“Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented: "This major breakthrough in the method of delivery of our CBR demonstrates that it could potentially be used as an off-the-shelf prevention and/or treatment for viral infections. Intranasal delivery of CBR would be both cost-efficient and easy to administer, making it ideal for the protection of both the civilian population and in biodefense."

We know Prevail Partners has announced they are committed partners.

We know they have invested in Hemogenyx at 6 pence in the past.

I personally doubt very much that they are here for just doubling up their investment.

And if that is true, then anyone buying at these low prices is going to do a fantastic deal.

I expect that some sort of funding will be announced later.

Maybe today, maybe tomorrow, maybe next week.

But I am sure that it will indeed be announced.

@Bullsbears

That is an easy one.

I would be happy to part with 90% of my holding @ 10 pounds

But that is still years in the future.

@HedgeHogarth

On this remarkable day, I would especially like to thank you and JustHereForHemo and Haywin and a couple of others for all the great post and info you have shared.

And regarding HEMO, o think it is worth paying attention to Dr. Sandler's words:

"The removal of the clinical hold was made possible by the hard work and dedication of the entire Hemogenyx Pharmaceuticals team and its Board of Directors and advisors."

Sorry for any potential confusion.

I for got the word NOT in the first line

The red dot did indicate the RNS that I was hoping for.

But this was none the less great news.

A patent granted in the US.

And I in particular liked the following lines:

"This also solidifies our Company's position as a leader in the area of conditioning bone marrow transplants".

What is not to like in a statement like that.

It goes to show that there is so much more to Hemogenyx, and that we can expect big things to come in the future, when we get funds to pay for the research and tests.

Personally I am on the fence if those funds should come through a sale of HEMO CAR-T.

Not that I am against it per see, but I wouldn't mind if we proved it up and went alone with the product and kept all the proceeds for ourselves.

In my view Mr. Sandler has kept that option open with the arrangement he has with our landlord that allows to move to bigger premises if needs be.

Just some assumptions:

70 people diagnosed with AML in the US daily, and 30% are eligible for our product.

So around 20 people a day.

Hemo should be capable of managing a number like that in a few years time.

Funding?

Issue extra shares, prove up the concept and then debt for the rest.

When we get revenue then we will have funds for CDX and CBR.

But I admit it is the slow way.

Maybe a sale of CAR-T will accelerate progress with the other candidates.

I was also relieved that there was no red dot this morning.

With a 28% rise yesterday and a RNS this morning, it would be hard not to draw a conclusion that something had leaked.

Now, that does not need to be the first line of thought.

So question is, have we gotten new investors on board or is it shorts closing?

I first expect to see a whole new sort of investors after it have been announced that we are clinical.

But until then, welcome to any newbies, in my humble opinion you have chosen well to join us at this time on the journey.

@Moorscloud

I do think Mr Sandler cares about the share price.

I also think that he cares about integrety.

And that is certain the science will speak for itself and when does, that he believes the share price ought to behave accordingly.

I also believes that he is not interested in pumping out hot air to inflate the share price and please impatient investors.

It will come when it comes.

It is because of the science that we know about in official RNS' and what I perceive to be a cavalier attitude that I have invested more in this company then is advised in any textbook.

Not long to go now.